Research & Literature

Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index.

Silverstein MJ, Lagios MD

The breast journal 2015; (21(2)):127-32 doi:10.1111/tbj.12368.

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.

Elshof LE, Tryfonidis K, Slaets L, et al.

European journal of cancer (Oxford, England : 1990) 2015; (51(12)):1497-510.

Predictors and patterns of fear of cancer recurrence in breast cancer survivors.

McGinty HL, Small BJ, Laronga C, Jacobsen PB

Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2016; (35(1)):1-9 doi:10.1037/hea0000238.

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.

Rakovitch E, Nofech-Mozes S, Hanna W, et al.

Breast cancer research and treatment 2015; (152(2)):389-98 doi:10.1007/s10549-015-3464-6.

Histopathological grading of breast ductal carcinoma in situ: validation of a web-based survey through intra-observer reproducibility analysis.

Schuh F, Biazús JV, Resetkova E, et al.

Diagnostic pathology 2015; (10()):93 doi:10.1186/s13000-015-0320-2.

Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

Narod SA, Iqbal J, Giannakeas V, et al.

JAMA oncology 2015; (1(7)):888-96 doi:10.1001/jamaoncol.2015.2510.

Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.

Davis JE, Nemesure B, Mehmood S, et al.

Applied immunohistochemistry & molecular morphology : AIMM 2016; (24(1)):20-5 doi:10.1097/PAI.0000000000000223.

Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.

Russell TD, Jindal S, Agunbiade S, et al.

The American journal of pathology 2015; (185(11)):3076-89.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, et al.

Lancet (London, England) 2016; (387(10021)):866-73.

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Margolese RG, Cecchini RS, Julian TB, et al.

Lancet (London, England) 2016; (387(10021)):849-56.

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Ganz PA, Cecchini RS, Julian TB, et al.

Lancet (London, England) 2016; (387(10021)):857-65.

Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?

Pilewskie M, Karsten M, Radosa J, et al.

Annals of surgical oncology 2016; (23(7)):2229-34 doi:10.1245/s10434-016-5145-z.

The relationship between illness representations, risk perception and fear of cancer recurrence in breast cancer survivors.

Freeman-Gibb LA, Janz NK, Katapodi MC, et al.

Psycho-oncology 2017; (26(9)):1270-1277 doi:10.1002/pon.4143.

Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?

Pilewskie M, Stempel M, Rosenfeld H, et al.

Annals of surgical oncology 2016; (23(11)):3487-3493 doi:10.1245/s10434-016-5268-2.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ.

Morrow M, Van Zee KJ, Solin LJ, et al.

Annals of surgical oncology 2016; (23(12)):3801-3810 doi:10.1245/s10434-016-5449-z.

The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis.

Marinovich ML, Azizi L, Macaskill P, et al.

Annals of surgical oncology 2016; (23(12)):3811-3821 doi:10.1245/s10434-016-5446-2.

Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Lyman GH, Somerfield MR, Bosserman LD, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(5)):561-564 doi:10.1200/JCO.2016.71.0947.

Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.

Lazzeroni M, Dunn BK, Pruneri G, et al.

Cancer treatment reviews 2017; (55()):1-9 doi:10.1016/j.ctrv.2017.01.010.

Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.

Tadros AB, Smith BD, Shen Y, et al.

Annals of surgery 2019; (269(1)):150-157 doi:10.1097/SLA.0000000000002439.

Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.

Grimm LJ, Ryser MD, Partridge AH, et al.

Annals of surgical oncology 2017; (24(12)):3534-3540 doi:10.1245/s10434-017-6018-9.

Adjuvant radiotherapy versus observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized controlled trials.

Garg PK, Jakhetiya A, Pandey R, et al.

The breast journal 2018; (24(3)):233-239 doi:10.1111/tbj.12889.

Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience.

Jethwa KR, Kahila MM, Mara KC, et al.

Breast cancer research and treatment 2018; (169(1)):189-196 doi:10.1007/s10549-018-4665-6.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(3)):310-320 doi:10.6004/jnccn.2018.0012.

Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.

Miligy IM, Gorringe KL, Toss MS, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(12)):1807-1815 doi:10.1038/s41379-018-0086-7.

Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy.

Fleming CA, Heneghan HM, O'Brien D, et al.

The British journal of surgery 2018; (105(9)):1098-1106 doi:10.1002/bjs.10899.

Ductal carcinoma in situ current trends, controversies, and review of literature.

Hong YK, McMasters KM, Egger ME, Ajkay N

American journal of surgery 2018; (216(5)):998-1003 doi:10.1016/j.amjsurg.2018.06.013.

Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm.

Hamilton SN, Nichol A, Wai E, et al.

International journal of radiation oncology, biology, physics 2019; (103(2)):381-388 doi:10.1016/j.ijrobp.2018.09.022.

Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.

Yan Y, Zhang L, Tan L, et al.

Pathology oncology research : POR 2020; (26(1)):521-531 doi:10.1007/s12253-018-0553-y.

The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).

Hwang ES, Hyslop T, Lynch T, et al.

BMJ open 2019; (9(3)):e026797 doi:10.1136/bmjopen-2018-026797.

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.

DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(19)):1629-1637 doi:10.1200/JCO.18.01779.

Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses.

Visser LL, Groen EJ, van Leeuwen FE, et al.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019; (28(5)):835-845 doi:10.1158/1055-9965.EPI-18-0976.

Ductal carcinoma in situ: to treat or not to treat, that is the question.

van Seijen M, Lips EH, Thompson AM, et al.

British journal of cancer 2019; (121(4)):285-292 doi:10.1038/s41416-019-0478-6.

Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score.

Van Zee KJ, Zabor EC, Di Donato R, et al.

Annals of surgical oncology 2019; (26(10)):3282-3288 doi:10.1245/s10434-019-07537-y.

[Ductal carcinoma in situ in 2019: Diagnosis, treatment, prognosis].

Cutuli B

Presse medicale (Paris, France : 1983) 2019; (48(10)):1112-1122 doi:10.1016/j.lpm.2019.08.018.

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.

Whelan TJ, Julian JA, Berrang TS, et al.

Lancet (London, England) 2019; (394(10215)):2165-2172 doi:10.1016/S0140-6736(19)32515-2.

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.

Allison KH, Hammond MEH, Dowsett M, et al.

Archives of pathology & laboratory medicine 2020; (144(5)):545-563 doi:10.5858/arpa.2019-0904-SA.

Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins.

Suzuki R, Yoshida M, Oguchi M, et al.

Journal of radiation research 2020; (61(3)):440-446 doi:10.1093/jrr/rraa005.

Analysis of Surgical Trends for Axillary Lymph Node Management in Patients with Ductal Carcinoma In Situ Using the NSQIP Database: Are We Following National Guidelines?

Pyfer BJ, Jonczyk M, Jean J, et al.

Annals of surgical oncology 2020; (27(9)):3448-3455 doi:10.1245/s10434-020-08374-0.

Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?

Oseni TO, Smith BL, Lehman CD, et al.

Annals of surgical oncology 2020; (27(11)):4459-4465 doi:10.1245/s10434-020-08576-6.

Is There Any Association Between Mammographic Features of Microcalcifications and Breast Cancer Subtypes in Ductal Carcinoma In Situ?

Avdan Aslan A, Gültekin S, Esendağli Yilmaz G, Kurukahvecioğlu O

Academic radiology 2021; (28(7)):963-968 doi:10.1016/j.acra.2020.05.032.

An Integrative Review on Factors Contributing to Fear of Cancer Recurrence Among Young Adult Breast Cancer Survivors.

Gormley M, Ghazal L, Fu MR, et al.

Cancer nursing 2022; (45(1)):E10-E26 doi:10.1097/NCC.0000000000000858.

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug.

Emons G, Mustea A, Tempfer C

Cancers 2020; (12(9)) doi:10.3390/cancers12092535.

Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.

Offersen BV, Alsner J, Nielsen HM, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(31)):3615-3625 doi:10.1200/JCO.20.01363.

Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.

Shaaban AM, Hilton B, Clements K, et al.

British journal of cancer 2021; (124(5)):1009-1017 doi:10.1038/s41416-020-01152-5.

Clinical outcomes of patients with ductal carcinoma in situ in Hong Kong: 10-year territory-wide cancer registry study.

Co M, Ngan RKC, Mang OWK, et al.

Hong Kong medical journal = Xianggang yi xue za zhi 2020; (26(6)):486-491 doi:10.12809/hkmj198203.

Symptomatic ductal carcinoma in situ (DCIS): Upstaging risk and predictors.

Venkatesh SL, Oseni TO, Bahl M

Clinical imaging 2021; (73()):101-107 doi:10.1016/j.clinimag.2020.11.050.

Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.

Cobleigh MA, Anderson SJ, Siziopikou KP, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(21)):2367-2374 doi:10.1200/JCO.20.02824.

Breast ductal carcinoma in situ with micro-invasion versus ductal carcinoma in situ: a comparative analysis of clinicopathological and mammographic findings.

Zhang M, Lin Q, Su XH, et al.

Clinical radiology 2021; (76(10)):787.e1-787.e7 doi:10.1016/j.crad.2021.04.011.

Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.

Gaudio A, Xourafa A, Rapisarda R, Castellino P

Endocrine, metabolic & immune disorders drug targets 2022; (22(3)):259-273 doi:10.2174/1871530321666210809153152.

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.

McCormick B, Winter KA, Woodward W, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(32)):3574-3582 doi:10.1200/JCO.21.01083.

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.

van Seijen M, Lips EH, Fu L, et al.

British journal of cancer 2021; (125(10)):1443-1449 doi:10.1038/s41416-021-01496-6.

Assessment of the usefulness of prognostic Van Nuys Prognostic Index in the treatment in ductal carcinoma in situ in 15-year observation.

Kunkiel M, Niwińska A

Scientific reports 2021; (11(1)):22645 doi:10.1038/s41598-021-02126-0.

Ductal Carcinoma in Situ: State-of-the-Art Review.

Grimm LJ, Rahbar H, Abdelmalak M, et al.

Radiology 2022; (302(2)):246-255 doi:10.1148/radiol.211839.

Systemic Treatment of Ductal Carcinoma In Situ of the Breast.

Crimini E, Corti C, Repetto M, et al.

Chirurgia (Bucharest, Romania : 1990) 2021; (116(5 Suppl)):S97-S104.

A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast.

Nicosia L, Bozzini AC, Penco S, et al.

Cancers 2022; (14(2)) doi:10.3390/cancers14020370.

The effect of psychological interventions on fear of cancer recurrence in breast cancer survivors: A systematic review and meta-analysis.

Lyu MM, Siah RC, Lam ASL, Cheng KKF

Journal of advanced nursing 2022; (78(10)):3069-3082 doi:10.1111/jan.15321.

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.

Chua BH, Link EK, Kunkler IH, et al.

Lancet (London, England) 2022; (400(10350)):431-440 doi:10.1016/S0140-6736(22)01246-6.

MiRNA expression deregulation correlates with the Oncotype DX® DCIS score.

Loudig O, Mitchell MI, Ben-Dov IZ, et al.

Breast cancer research : BCR 2022; (24(1)):62 doi:10.1186/s13058-022-01558-4.

Precise application of sentinel lymph node biopsy in patients with ductal carcinoma in situ: A systematic review and meta-analysis of real-world data.

Chiu CW, Chang LC, Su CM, et al.

Surgical oncology 2022; (45()):101880 doi:10.1016/j.suronc.2022.101880.

The clinical significance of HER2 expression in DCIS.

Akrida I, Mulita F

Medical oncology (Northwood, London, England) 2022; (40(1)):16 doi:10.1007/s12032-022-01876-9.

Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ.

Byng D, Thomas SM, Rushing CN, et al.

Radiology 2023; (307(1)):e221210 doi:10.1148/radiol.221210.

Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature.

Christensen Holz S

Current oncology reports 2023; (25(7)):825-831 doi:10.1007/s11912-023-01413-5.

De-escalation of Sentinel Lymph Node Biopsy in Patients With Ductal Carcinoma In Situ.

Abdulla HA, Khalaf Y

Cureus 2023; (15(4)):e37383 doi:10.7759/cureus.37383.

Isogenic Mammary Models of Intraductal Carcinoma Reveal Progression to Invasiveness in the Absence of a Non-Obligatory In Situ Stage.

Bernhardt SM, Mitchell E, Stamnes S, et al.

Cancers 2023; (15(8)) doi:10.3390/cancers15082257.

Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?

Hahn E, Rodin D, Sutradhar R, et al.

Current oncology (Toronto, Ont.) 2023; (30(6)):5795-5806 doi:10.3390/curroncol30060433.

Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study.

Wheelwright S, Matthews L, Jenkins V, et al.

Trials 2023; (24(1)):670 doi:10.1186/s13063-023-07703-4.

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

Schmitz RSJM, van den Belt-Dusebout AW, Clements K, et al.

BMJ (Clinical research ed.) 2023; (383()):e076022 doi:10.1136/bmj-2023-076022.

Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.

Bae SJ, Kook Y, Jang JS, et al.

Breast cancer research : BCR 2024; (26(1)):65 doi:10.1186/s13058-024-01816-7.

Mammography of suspicious calcifications among ductal carcinoma in situ and benign breast disease.

Lohitvisate W, Kaeorat C, Kwankua A

SA journal of radiology 2024; (28(1)):2852 doi:10.4102/sajr.v28i1.2852.

Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.

Nashimoto M, Asano Y, Matsui H, et al.

Breast cancer (Tokyo, Japan) 2024; (31(6)):1010-1017 doi:10.1007/s12282-024-01613-2.

Radiology for Ductal Carcinoma In Situ of the Breast: Updates on Invasive Cancer Progression and Active Monitoring.

Grimm LJ

Korean journal of radiology 2024; (25(8)):698-705 doi:10.3348/kjr.2024.0117.

Proportion of Patients With Ductal Carcinoma In Situ That Qualify for Observation Criteria Set Forth by Clinical Trials.

McAdams CD, Clevenger N, Nicholson K, et al.

Journal of surgical oncology 2025; (131(2)):115-123 doi:10.1002/jso.27858.

A Nomogram Using Imaging Features to Predict Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.

Choi BH, Kang S, Cho N, Kim SY

Korean journal of radiology 2024; (25(10)):876-886 doi:10.3348/kjr.2024.0268.

Spectrum of Ductal Carcinoma In Situ (DCIS) Lesions of the Breast: From Morphology to Molecular Characteristics.

Sathvik G, V P, Joseph LD, Challa CB

Cureus 2024; (16(9)):e69929 doi:10.7759/cureus.69929.

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.

Hwang ES, Hyslop T, Lynch T, et al.

JAMA 2025; (333(11)):972-980 doi:10.1001/jama.2024.26698.

The natural history of ductal carcinoma in situ: development, validation, and estimated outcomes of the SimDCIS model.

Poelhekken K, Dorrius MD, Dibden A, et al.

Breast cancer research and treatment 2025; (211(1)):223-231 doi:10.1007/s10549-025-07639-0.

Comparative Analyses of Van Nuys Prognostic Index and NCCN Guidelines in Ductal Carcinoma In Situ Treatment in a Brazilian Hospital.

Antonini M, Barros Vasconcelos R, Mattar A, et al.

Life (Basel, Switzerland) 2025; (15(3)) doi:10.3390/life15030432.

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.

Park KU, Somerfield MR, Anne N, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(14)):1720-1741 doi:10.1200/JCO-25-00099.

Oncotype DX Breast DCIS Score® Test: Impact on Radiotherapy Recommendations and Patient Decisional Anxiety.

Muktar S, Kirby A, Locke I, et al.

Clinical oncology (Royal College of Radiologists (Great Britain)) 2025; (42()):103839 doi:10.1016/j.clon.2025.103839.

ACR Appropriateness Criteria® Imaging of Ductal Carcinoma in Situ (DCIS).

, Kuzmiak CM, Sharpe RE, et al.

Journal of the American College of Radiology : JACR 2025; (22(5S)):S274-S299 doi:10.1016/j.jacr.2025.02.027.

The effects of adjuvant endocrine therapy on long-term outcomes from ductal carcinoma in situ: a systematic review and meta-analysis.

Chen Q, Campbell I, Elwood M, et al.

Breast (Edinburgh, Scotland) 2025; (82()):104521 doi:10.1016/j.breast.2025.104521.

Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.

Choi S, Park B, Lee EG, et al.

Breast cancer research and treatment 2025; (213(3)):325-334 doi:10.1007/s10549-025-07768-6.

Advancements in Detection and Management of Ductal Carcinoma in Situ.

Tucunduva TCM, Zanetta VC, Chala LF, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(9)):e240174 doi:10.1148/rg.240174.

Multimodal Imaging of Ductal Carcinoma In Situ: A Single-Center Study of 75 Cases.

Urraro F, Giordano N, Patanè V, et al.

Medical sciences (Basel, Switzerland) 2025; (13(4)) doi:10.3390/medsci13040245.

Preliminary Outcomes of a Culturally Adapted Fear of Recurrence Therapy (FORT) for Turkish Breast Cancer Survivors: A Randomized Controlled Trial.

Eyrenci A, Ertuna L, Bahçivan O

Psycho-oncology 2025; (34(12)):e70345 doi:10.1002/pon.70345.

American Radium Society Appropriate Use Criteria Report on Radiation in the Management of Ductal Carcinoma in Situ (DCIS) of the Breast.

Harris E, Daroui P, Gonzalez V, et al.

Clinical breast cancer 2026; (26(2)):105-112 doi:10.1016/j.clbc.2025.12.007.

Calcification and tumour-infiltrating lymphocytes predict upgrade of human epidermal growth factor 2 (HER2)-negative ductal carcinoma in situ diagnosed on core needle biopsy.

Marabi M, Li Y, Aphivatanasiri C, et al.

Histopathology 2026; (89(1)):122-135 doi:10.1111/his.70143.

Artificial Intelligence-Assisted Invasion Risk Scoring in Tru-Cut Biopsies of Ductal Carcinoma in Situ; Predictive Role of Estrogen Receptor and HER2 Expression.

Uzun E, Bulut K

Turk patoloji dergisi 2026; (42(3)):174-182 doi:10.5146/tjpath.2026.14901.